

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

IPW

<p><i>(This form may be used for all correspondence after initial filing)</i></p>		Application Number	10/566,410
		Filing Date	January 30, 2006
		First Named Inventor	Deborah Hurst
		Art Unit	
		Examiner Name	
Total Number of Pages in This Submission		Attorney Docket Number	59516-313

## ENCLOSURES (check all that apply)

<input type="checkbox"/> Fee Transmittal Form  <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment / Reply  <input type="checkbox"/> After Final  <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request  <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application  <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s)  <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition  <input type="checkbox"/> Petition to Convert to a Provisional Application  <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer  <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____  <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC  <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences  <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)  <input type="checkbox"/> Proprietary Information  <input type="checkbox"/> Status Letter  <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):  Return Postcard	
		<b>Remarks</b>	

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm	Davis Wright Tremaine LLP		
Signature			
Printed Name	Jane E. R. Potter		
Date	April 16, 2007	Reg. No.	33,332

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Signature	
Typed or printed name	S. Sheridan
Date	April 16, 2007

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



EXPRESS MAIL NO.

PATENT

I hereby certify that on the date specified below, this correspondence is being deposited with the United States Postal Service as first-class mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

April 16, 2007

Date



Sharon Sheridan

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Deborah Hurst  
Application No. : 10/566,410  
Filed : January 30, 2006  
For : METHODS OF THERAPY FOR CHRONIC LYMPHOCYTIC  
LEUKEMIA

Docket No. : 59516-313

Date : April 16, 2007

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents:

In accordance with 37 C.F.R. §§ 1.56 and 1.97 through 1.98, applicants wish to make known to the Patent and Trademark Office the references set forth on the attached form PTO/SB/08. Copies of the references are enclosed. As to any reference supplied, applicants do not admit that it is "prior art" under 35 U.S.C. §§ 102 or 103, and specifically reserve the right to traverse or antedate any such reference, as by a showing under 37 C.F.R. § 1.131 or other method. Although the aforesaid references are made known to the Patent and Trademark Office in compliance with applicants' duty to disclose all information they are aware of which is believed relevant to the

examination of the above-identified application, applicants believe that their invention is patentable.

Please acknowledge receipt of this Information Disclosure Statement and kindly make the cited references of record in the above-identified application. No fee is due at this time in accordance with 37 C.F.R. § 1.97(b).

Respectfully submitted,  
Deborah Hurst  
DAVIS WRIGHT TREMAINE LLP

  
By \_\_\_\_\_  
Jane E. R. Potter  
Registration No. 33,332

Enclosure:

Postcard  
Form PTO/SB/08  
Cited References (6)

2600 Century Square  
1501 Fourth Avenue  
Seattle, WA 98101-1688  
Phone: (206) 622-3150  
Facsimile: (206) 628-7699



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Patent & Trademark Office  
Information Disclosure Statement  
for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

1

### Complete if Known

Application Number	10/566,410
Filing Date	January 30, 2006
First Named Inventor	Deborah Hurst
Art Unit	
Examiner Name	

Attorney Docket Number

59516-313

### NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		BARNGROVER, D., Recombinant Interleukin-2 (aldesleukin) for Oncology and HIV Disease and Recombinant Protein Treatment (Fabrazyme) for Fabry's Disease (No. 14 in a Series of Articles to Promote a Better Understanding of the Use of Genetic Engineering, <i>J Biotechnology</i> 95:277-283, 2002).	
		DMOSZYNSKA, A. et al., Attempted Reconstruction of the Immune System Using Low Doses of Interleukin 2 in Chronic Lymphocytic Leukemia Patients Treated with 2-Chlorodeoxyadenosine: Results of a Pilot Study, <i>Leukemia and Lymphoma</i> 34(3-4):335-340, 1999.	
		KAY, N. E. et al., Evidence for Tumor Reduction in Refractory or Relapsed B-CLL Patients with Infusional Interleukin-2, <i>Nouv Rev Fr Hematol</i> 30:475-478, 1988.	
		MORRISON, V. A., Update on Prophylaxis and Therapy of Infection in Patients with Chronic Lymphocytic Leukemia, <i>Expert Rev. Anticancer Ther.</i> 1(1):84-90, 2001.	
		OSTERBORG, A. et al., Phase II Multicenter Study of Human CD52 Antibody in Previously Treated Chronic Lymphocytic Leukemia, <i>J Clinical Oncology</i> 15(4):1567-1574, 1997.	
		WIERDA, W. G. and O'BRIEN, S., Immunotherapy of Chronic Lymphocytic Leukemia, <i>Expert Rev. Anticancer Ther.</i> 1(1):73-83, 2001.	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.